Interesting (and not much discussed) aspects relevant for the choice of basal insulin

Česká verzia

Authors: Peter Novodvorský ^1,2,3
Authors place of work: metabolické centrum s. r. o., Trenčín ¹; Centrum diabetologie IKEM, Praha ²; Department of Oncology and Metabolism, Medical School, University of Sheffield, United Kingdom ³
Published in the journal: Diab Obez 2021; 21(42): 90-94
Category: Reviews

Summary

Several basal insulins are currently available on the market. This makes the task of choosing the optimal basal insulin for a particular patient a more complex one. Several aspects, not so important in the past, have now become more relevant in this process. In this paper I discuss the differences of basal insulin analogues in relation to their effect on body weight, the possible effect of hypoalbuminaemia on the risk of hypoglycaemia that might be linked with differences in pharmacokinetics of individual basal insulin analogues and I also discuss the flexibility in dosing time of basal insulin analogues of 2^nd generation.

Keywords:

Body weight – basal insulin – glargine 300 U/ml – hypoglycaemia – albuminaemia – flexibility in dosing time of basal insulin – type 2 diabetes (2TD)

Zdroje

1. Davies MJ, D’Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41(12): 2669– 2701. Dostupné z DOI:<http://dx.doi.org/10.2337/dci18–0033> .

2. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-- causes, effects and coping strategies. Diabetes Obes Metab 2007; 29(6): 2799–2812. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463–1326.2006.00686.x>.

3. Madenidou AV, Paschos P, Karagiannis T et al. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med 2018; 169(3): 165–174. Dostupné z DOI: <http://dx.doi.org/10.7326/M18–0443>.

4. Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015; 17(9): 859–867. Dostupné z DOI:<http://dx.doi.org/10.1111/dom.12485> .

5. Rosenstock J, Cheng A, Ritzel R et al. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care 2018; 41(10): 2147–2154. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18–0559>.

6. Philis-Tsimikas A, Klonoff DC, Khunti K et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin- treated patients with type 2 diabetes: the randomised, head-tohead CONCLUDE trial. Diabetologia 2020; 63(4): 698–710. Dostupné z DOI:<http://dx.doi.org/10.1007/s00125–019–05080–9> .

7. Kawaguchi Y, Sawa J, Sakuma N et al. Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles. J Diabetes Investig 2019; 10(2): 343–351. Dostupné z DOI: <http://dx.doi.org/10.1111/jdi.12884>.

8. Yamabe M, Kuroda M, Hirosawa Y et al. Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study. J Diabetes Investig 2019; 10(2): 352–357. Dostupné z DOI:<http://dx.doi.org/10.1111/jdi.12894> .

9. Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat Rev Endocrinol 2017; 13(7): 385–399. Dostupné z DOI:<http://dx.doi.org/10.1038/nrendo.2017.39> .

10. Hochberg I. Insulin Detemir Use Is Associated With Higher Occurrence of Hypoglycemia in Hospitalized Patients With Hypoalbuminemia. Diabetes Care 2018; 41(4): e44-e46.<http://dx.doi.org/10.2337/dc17–1957>.

11. Haluzík M, Phillis-Tsimikas A, Bosnyak Z et al. Differences in HbA1c lowering effect and hypoglycemia risk between Gla 300 and IDeg according to renal function in the BRIGHT Trial. ADA 79th Scientific Sessions; 7–11th June 2019; San Francisco, USA. Diabetes 2019; 68(Suppl 1): 146-OR. Dostupné z DOI:<https://doi.org/10.2337/db19–146-OR>

12. Charbonnel B, Vanita RA, Westerbacka J et al. Differences in HbA1c reduction between insulin glargine 300 U/mL (Gla-300) and insulin degludec100 U/mL (IDeg-100) in adults ≥70 years of age with T2DM in the BRIGHT trial. ADA 79th Scientific Sessions; 7–11th June 2019; San Francisco, USA. Diabetes 2019; 68(Suppl 1): 131-OR. Dostupné z DOI:<https://doi.org/10.2337/db19–131-LB> .

13. Kawaguchi Y, Sawa J, Hamai C et al. Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec. Diabetes Ther 2019; 10(4): 1535–1541. Dostupné z DOI:<http://dx.doi.org/10.1007/s13300–019–0654-y>.

14. Jubiz W, Canterbury JM, Reiss E et al. Circadian rhythm in serum parathyroid hormone concentration in human subjects: correlation with serum calcium, phosphate, albumin, and growth hormone levels. J Clin Invest 1972; 51(8): 2040–2046. Dostupné z DOI: <http://dx.doi.org/10.1172/JCI107010>.

15. Caprio S, Amiel S, Tamborlane WV et al. Defective free-fatty acid and oxidative glucose metabolism in IDDM during hypoglycemia. Influence of glycemic control. Diabetes 1990; 39(2): 134–141. Dostupné z DOI:<http://dx.doi.org/10.2337/diab.39.2.134>.

16. Kurtzhals P, Havelund S, Jonassen I et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995; 312 (Pt 3): 725– 731. Dostupné z DOI: <http://dx.doi.org/10.1042/bj3120725>.

17. Battelino T, Bosnyak Z, Danne T et al. InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design. Diabetes Ther 2020; 11(4): 1017–1027. Dostupné z DOI: . Erratum in Correction to: In- Range: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design. Battelino T, Bosnyak Z, Danne T et al. Diabetes Ther 2020; 11(7): 1607–1608. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–020–00820–2>.

18. Battelino T, Bosnyak Z, Danne T et al. Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design. Diabetes Ther 2020; 11(8): 1907–1908. Dostupné z DOI:<http://dx.doi.org/10.1007/s13300–020–00853–7>.

19. Toujeo. Súhrn charakteristických vlastností lieku. Dostupné z WWW: . 20. Tresiba. Súhrn charakteristických vlastností lieku. Dostupné z WWW:<https://www.ema.europa.eu/en/documents/product-information/toujeo-epar-product-information_sk.pdf>.

20. Tresiba. Súhrn charakteristických vlastností lieku. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/ product-information/tresiba-epar-product-information_sk.pdf>.